SCHEMBL2352467

SCHEMBL2352467

Cc1nc2ccc(Cl)cn2c1-c1csc(Nc2ccc(N(C)C)cc2)n1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 9/20 0.59
GAA P10253 8/20 0.59
ALDH1A1 P00352 6/20 0.59
SMN1; SMN2 Q16637 5/20 0.59
RAB9A P51151 4/20 0.59
TDP1 Q9NUW8 2/20 0.59
L3MBTL1 Q9Y468 2/20 0.59
KDM4E B2RXH2 5/20 0.54
LMNA P02545 4/20 0.54
HTT P42858 4/20 0.54
MEN1 O00255 3/20 0.54
KMT2A Q03164 3/20 0.54
NPSR1 Q6W5P4 2/20 0.54
HPGD P15428 2/20 0.54
ALOX12 P18054 2/20 0.54
PRKD3 O94806 1/20 0.53
MAP4K4 O95819 1/20 0.53
PIM1 P11309 1/20 0.53
RPS6KB1 P23443 1/20 0.53
CDK2 P24941 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Bromide SCHEMBL18040756 0.99 MAPT (0.61) MAPTGAAALDH1A1SMN1; SMN2RAB9A
SCHEMBL1684636 0.91 MAPT (0.60) MAPTGAAALDH1A1SMN1; SMN2RAB9A
Bromide SCHEMBL18040665 0.90 MAPT (0.62) MAPTGAAALDH1A1SMN1; SMN2RAB9A
SCHEMBL1684754 0.89 MAPT (0.62) MAPTGAAALDH1A1SMN1; SMN2RAB9A
SCHEMBL2354901 0.89 MAPT (0.67) MAPTGAAALDH1A1SMN1; SMN2RAB9A
SCHEMBL2354317 0.89 GAA (0.52) MAPTGAAALDH1A1SMN1; SMN2RAB9A
Bromide SCHEMBL18040800 0.88 MAPT (0.64) MAPTGAAALDH1A1SMN1; SMN2RAB9A
Bromide SCHEMBL18040775 0.88 MAPT (0.69) MAPTGAAALDH1A1SMN1; SMN2RAB9A
Bromide SCHEMBL18040658 0.88 GAA (0.53) MAPTGAAALDH1A1SMN1; SMN2RAB9A
SCHEMBL1684619 0.88 MAPT (0.59) MAPTGAAALDH1A1SMN1; SMN2RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2306836-B1 BMI-1 PROTEIN EXPRESSION MODULATORS PTC THERAPEUTICS INC (US) 2016-09-07 EP claimed
US-8680113-B2 BMI-1 protein expression modulators PTC THERAPEUTICS, INC. (US) 2014-03-25 US claimed
US-20110190239-A1 BMI-1 PROTEIN EXPRESSION MODULATORS PTC THERAPEUTICS, INC. (US) 2011-08-04 US claimed
EP-3111956-B1 BMI 1 PROTEIN EXPRESSION MODULATORS PTC THERAPEUTICS INC (US) 2019-05-08 EP disclosed
EP-3111956-A1 BMI 1 PROTEIN EXPRESSION MODULATORS PTC Therapeutics, Inc. (US) 2017-01-04 EP disclosed
EP-2306836-B1 BMI-1 PROTEIN EXPRESSION MODULATORS PTC THERAPEUTICS INC (US) 2016-09-07 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110190239-A1 BMI-1 PROTEIN EXPRESSION MODULATORS BMI1, CREBBP, BAZ2A MAPT 4026/4885GAA 3522/4885ALDH1A1 2357/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.